Technologies search results
11 Results for ''
MRBL: Next-Generation Gene Therapy for Molecular Skin Rejuvenation
The next-generation gene therapy for molecular skin rejuvenation combines a comprehensive target gene prediction with a novel transdermal delivery approach for therapeutic adenovirus-associated viruses. The platform targets monogenic disease indications in the skin, and extends the same targets to the treatment of common skin aging conditions.
Regenerating Tissues with Sustained Growth Factor Delivery
Millions of people worldwide suffer from traumatic injuries or health conditions that cause damage to soft tissues including nerves, muscles, and blood vessels. The body can heal some of that damage, but more serious cases like the severing of a nerve or sustained oxygen deprivation can lead to permanent loss of movement or sensation in...
Single-Cell Encapsulation for Improved Cell Therapies
Mesenchymal stromal cells (MSCs) are valued for their ability to secrete compounds that modulate the body’s immune system, making them an attractive solution for existing problems with cell therapies including host-vs-graft disease and organ transplant rejections. However, MSCs are rapidly cleared from the body and can come under fire from the immune system. Efforts to...
Brain Targeting Program: Shuttles for Brain Delivery of Therapeutics and Diagnostics
In its Brain Targeting Program, a Wyss team led by Founding Director Donald Ingber, M.D., Ph.D. and Staff Program Lead James Gorman, M.D., Ph.D. is developing improved approaches to target drugs and diagnostics to the brain. Leveraging the human blood-brain barrier (BBB) Chip technology developed by Ingber’s team, combined with advanced antibody R&D capabilities, the...
Injectable Alginate Hydrogels for Medical Applications
One of the biggest challenges in medicine is getting a drug to the right part of the body at the right time. Even when the target site in the body is known, like a pain-causing injury or a cancerous tumor, most drugs are given as oral pills or intravenous infusions, which limits their effectiveness. In...
Implantable Cancer Vaccine
The Wyss Institute’s implantable, biodegradable cancer vaccine leverages immunotherapeutic methods and could one day help overcome melanoma, other cancers, infectious diseases, auto-immune diseases, as well as vaccinate against specific peptides, proteins, or antigens. The implant is a biodegradable polymer scaffold containing growth factors and components of each patient’s tumors. The technology was initially designed to...
Microfluidic Drug Encapsulation
Because of their large molecular sizes and properties, biologic drugs, be it in the form of monoclonal antibodies that target disease-associated molecules or active proteins and enzymes that may correct deficiencies in the human body, have proven difficult to deploy in many cases. Their therapeutic effects on target cells and tissues often require high and...
DNA Nanostructures for Drug Delivery
Researchers at the Wyss Institute have developed two methods for building arbitrarily shaped nanostructures using DNA, with a focus on translating the technology towards nanofabrication and drug delivery applications. One proprietary nanofabrication technique, called “DNA-brick self-assembly,” uses short, synthetic strands of DNA that work like interlocking Lego® bricks. It capitalizes on the ability to program...
Over 15 million Americans are at risk of anaphylaxis, a severe allergic reaction triggered by exposure to certain foods, materials, medications, and insect bites. Every three minutes, a food reaction sends someone to the emergency room. In most individuals, anaphylactic shock can be prevented by administering the counteracting drug epinephrine, as soon as an attack...
NanoRx: Mechanically-Activated Drug Targeting
The Wyss team has developed a novel drug targeting nanotechnology that is activated locally by mechanical forces, either endogenous high shear stresses in blood created by vascular occlusion or mechanical energy applied locally using low-energy ultrasound radiation. Today, vascular blockage is the leading cause of death and disability in United States and Europe. Current therapies...
Organ Chips are microfluidic devices lined with living human cells for drug development, disease modeling, and personalized medicine. Launched in 2014, Wyss startup Emulate, Inc., is leveraging the Wyss Institute’s Organ Chip technology to mimic human organs in vitro, enabling faster, better, and cheaper drug development and insights into human health.